We Imagine
a society where diagnosis takes days, instead of years
We Challenge
the complexity of developing cures for rare diseases
We Engage
in dialogue with researchers, scientific community, industry, and regulators
We Envision
a world where all 7,000 rare diseases are understood

Life Science Venture Capital

Chiesi Ventures is a venture capital firm focused on the area of rare and orphan disorders. Our goal is to complement the strategic interest of the Chiesi Group by investing in early stage development opportunities. Chiesi Ventures also aim to accelerate the expansion of the Chiesi network in EU and the US among universities, venture capital investors, rare disease patient organizations and entrepreneurial companies developing treatments for rare diseases.

Hand with tech background Banner
Microscope Banner

Traditional small molecules and biologics

Formulation technologies and devices

Advanced therapies

Disease discovery, diagnosis and management

About Chiesi Ventures

UNIQUELY RARE

Chiesi Ventures is unique in its focus: improving quality of diagnosis, disease management, care and therapy to all patients affected by rare diseases.

We are creating a portfolio of companies focused specifically on the field of rare diseases but with complementary capabilities and missions.

The burden of Rare Diseases

Rare diseases are conditions affecting less than 200,000 people in the US and less than five (5) in 10,000 according to the definition adopted by the European Medicines Agency. An estimated 6,000 - 7,000 rare diseases have been diagnosed so far. Collectively, an estimated 30 million people are affected by a rare disease in Europe with a similar occurrence in the US. 80% of rare diseases have been described as genetic in nature.

Global Genes

Allies in Rare Diseases
GlobalGenes

Chiesi Ventures is unique in its focus: improving quality of diagnosis, disease management, care and therapy to all patients affected by rare diseases.

We are creating a portfolio of companies focused specifically on the field of rare diseases but with complementary capabilities and missions.

Strategies Image